LifeStance Health Group (NASDAQ:LFST) COO Lisa Miller Sells 47,912 Shares

LifeStance Health Group, Inc. (NASDAQ:LFST) COO Lisa Miller sold 47,912 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $10.85, for a total transaction of $519,845.20. Following the transaction, the chief operating officer owned 281,289 shares in the company, valued at approximately $3,051,985.65. This trade represents a 14.55% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

LifeStance Health Group Stock Up 6.3%

LFST stock opened at $12.23 on Thursday. The company has a fifty day moving average price of $10.19 and a 200 day moving average price of $8.16. LifeStance Health Group, Inc. has a 12 month low of $4.77 and a 12 month high of $12.43. The company has a market cap of $4.74 billion, a price-to-earnings ratio of 94.08 and a beta of 1.14. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.38 and a quick ratio of 1.38.

LifeStance Health Group (NASDAQ:LFST) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.03. The company had revenue of $435.35 million for the quarter, compared to the consensus estimate of $414.58 million. LifeStance Health Group had a net margin of 3.19% and a return on equity of 3.39%. LifeStance Health Group’s revenue for the quarter was up 26.1% on a year-over-year basis. During the same period last year, the firm posted ($0.01) EPS. Sell-side analysts expect that LifeStance Health Group, Inc. will post 0.15 earnings per share for the current year.

Key LifeStance Health Group News

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: Analyst support remains strong. Morgan Stanley reaffirmed its Buy rating, while BTIG Research recently raised its price target from $15 to $16 and maintained a Buy rating. These actions reinforce the bullish view of LifeStance’s growth prospects. Morgan Stanley Reaffirms Their Buy Rating on LifeStance Health Group
• Positive Sentiment: LifeStance’s earnings momentum is supporting the stock. The company recently exceeded quarterly earnings and revenue expectations, with revenue rising 26.1% year over year. Zacks also upgraded LFST to a Rank #2 (Buy), citing improving earnings prospects. LifeStance Health Upgraded to Buy
• Positive Sentiment: Investor interest has pushed LFST to a new 52-week high. The move reflects strong recent momentum and growing optimism about the company’s fundamentals, although the elevated valuation increases the importance of continued execution. LifeStance Health Group Sets New 1-Year High
• Neutral Sentiment: LifeStance released survey findings highlighting demand for mental-health services integrated into perimenopause and menopause care. The announcement supports awareness of a potential growth niche but does not directly change financial guidance. LifeStance Survey on Menopause Care
• Negative Sentiment: Several insiders reduced their holdings. Major shareholder TPG GP A sold 13.64 million shares for approximately $144.9 million, while the COO and CTO sold shares worth about $519,845 and $481,675, respectively. Although each seller retained a substantial position, the transactions may raise concerns about profit-taking and near-term selling pressure. LifeStance Insider Sale Filing

Institutional Investors Weigh In On LifeStance Health Group

A number of hedge funds have recently added to or reduced their stakes in LFST. Royal Bank of Canada increased its position in LifeStance Health Group by 63.4% during the 1st quarter. Royal Bank of Canada now owns 70,248 shares of the company’s stock worth $468,000 after purchasing an additional 27,244 shares during the period. AQR Capital Management LLC raised its stake in shares of LifeStance Health Group by 223.0% during the 1st quarter. AQR Capital Management LLC now owns 51,500 shares of the company’s stock worth $343,000 after buying an additional 35,554 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of LifeStance Health Group by 3.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 142,950 shares of the company’s stock valued at $952,000 after buying an additional 4,169 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of LifeStance Health Group by 1.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 615,652 shares of the company’s stock valued at $4,100,000 after buying an additional 11,331 shares during the period. Finally, JPMorgan Chase & Co. boosted its stake in shares of LifeStance Health Group by 10.2% in the second quarter. JPMorgan Chase & Co. now owns 550,657 shares of the company’s stock valued at $2,847,000 after buying an additional 51,154 shares in the last quarter. Institutional investors and hedge funds own 85.50% of the company’s stock.

Wall Street Analysts Forecast Growth

LFST has been the subject of several analyst reports. The Goldman Sachs Group initiated coverage on LifeStance Health Group in a research note on Friday, June 5th. They set a “neutral” rating and a $9.00 price objective for the company. JPMorgan Chase & Co. lifted their target price on LifeStance Health Group from $8.00 to $9.00 and gave the company a “neutral” rating in a research note on Thursday, May 14th. Zacks Research lowered LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. Barclays upped their price target on LifeStance Health Group from $9.00 to $13.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 14th. Finally, Wall Street Zen downgraded LifeStance Health Group from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 25th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $11.62.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.